288 related articles for article (PubMed ID: 25050322)
1. Metformin against cancer stem cells through the modulation of energy metabolism: special considerations on ovarian cancer.
Kim TH; Suh DH; Kim MK; Song YS
Biomed Res Int; 2014; 2014():132702. PubMed ID: 25050322
[TBL] [Abstract][Full Text] [Related]
2. Long term treatment of metformin impedes development of chemoresistance by regulating cancer stem cell differentiation through taurine generation in ovarian cancer cells.
Bishnu A; Sakpal A; Ghosh N; Choudhury P; Chaudhury K; Ray P
Int J Biochem Cell Biol; 2019 Feb; 107():116-127. PubMed ID: 30593952
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of midkine by metformin can contribute to its anticancer effects in malignancies: A proposal mechanism of action of metformin in context of endometrial cancer prevention and therapy.
Karadeniz Z; Aynacıoğlu AŞ; Bilir A; Tuna MY
Med Hypotheses; 2020 Jan; 134():109420. PubMed ID: 31634770
[TBL] [Abstract][Full Text] [Related]
4. Ovarian cancer stem cell: A potential therapeutic target for overcoming multidrug resistance.
Mihanfar A; Aghazadeh Attari J; Mohebbi I; Majidinia M; Kaviani M; Yousefi M; Yousefi B
J Cell Physiol; 2019 Apr; 234(4):3238-3253. PubMed ID: 30317560
[TBL] [Abstract][Full Text] [Related]
5. Metformin targets ovarian cancer stem cells in vitro and in vivo.
Shank JJ; Yang K; Ghannam J; Cabrera L; Johnston CJ; Reynolds RK; Buckanovich RJ
Gynecol Oncol; 2012 Nov; 127(2):390-7. PubMed ID: 22864111
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic mechanisms underlying antidiabetic drug metformin's chemopreventive effect against colorectal cancer.
Jaromy M; Miller JD
Eur J Pharmacol; 2021 Apr; 897():173956. PubMed ID: 33617821
[TBL] [Abstract][Full Text] [Related]
7. Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism.
Li SS; Ma J; Wong AST
J Gynecol Oncol; 2018 Mar; 29(2):e32. PubMed ID: 29468856
[TBL] [Abstract][Full Text] [Related]
8. Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.
Zhang F; Chen H; Du J; Wang B; Yang L
Med Sci Monit; 2018 Sep; 24():6093-6101. PubMed ID: 30171812
[TBL] [Abstract][Full Text] [Related]
9. Metformin Suppresses Tumor Progression by Inactivating Stromal Fibroblasts in Ovarian Cancer.
Xu S; Yang Z; Jin P; Yang X; Li X; Wei X; Wang Y; Long S; Zhang T; Chen G; Sun C; Ma D; Gao Q
Mol Cancer Ther; 2018 Jun; 17(6):1291-1302. PubMed ID: 29545331
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells.
Zhang R; Zhang P; Wang H; Hou D; Li W; Xiao G; Li C
Stem Cell Res Ther; 2015 Dec; 6():262. PubMed ID: 26718286
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis and cancer stem cells: New perspectives on therapy of ovarian cancer.
Markowska A; Sajdak S; Markowska J; Huczyński A
Eur J Med Chem; 2017 Dec; 142():87-94. PubMed ID: 28651817
[TBL] [Abstract][Full Text] [Related]
12. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
Dos Santos Guimarães I; Ladislau-Magescky T; Tessarollo NG; Dos Santos DZ; Gimba ERP; Sternberg C; Silva IV; Rangel LBA
Pharmacol Rep; 2018 Jun; 70(3):409-417. PubMed ID: 29627688
[TBL] [Abstract][Full Text] [Related]
13. Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism.
Liao J; Qian F; Tchabo N; Mhawech-Fauceglia P; Beck A; Qian Z; Wang X; Huss WJ; Lele SB; Morrison CD; Odunsi K
PLoS One; 2014; 9(1):e84941. PubMed ID: 24409314
[TBL] [Abstract][Full Text] [Related]
14. Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: Perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells.
Ahmed N; Escalona R; Leung D; Chan E; Kannourakis G
Semin Cancer Biol; 2018 Dec; 53():265-281. PubMed ID: 30317036
[TBL] [Abstract][Full Text] [Related]
15. Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation.
Hu T; Chung YM; Guan M; Ma M; Ma J; Berek JS; Hu MC
Sci Rep; 2014 Jul; 4():5810. PubMed ID: 25056111
[TBL] [Abstract][Full Text] [Related]
16. BAG3 epigenetically regulates GALNT10 expression via WDR5 and facilitates the stem cell-like properties of platin-resistant ovarian cancer cells.
Zhao FY; Zhang Q; Wang JM; Jiang JY; Huyan LY; Liu BQ; Yan J; Li C; Wang HQ
Biochim Biophys Acta Mol Cell Res; 2021 Aug; 1868(9):119077. PubMed ID: 34111434
[TBL] [Abstract][Full Text] [Related]
17. Rad6 upregulation promotes stem cell-like characteristics and platinum resistance in ovarian cancer.
Somasagara RR; Tripathi K; Spencer SM; Clark DW; Barnett R; Bachaboina L; Scalici J; Rocconi RP; Piazza GA; Palle K
Biochem Biophys Res Commun; 2016 Jan; 469(3):449-55. PubMed ID: 26679603
[TBL] [Abstract][Full Text] [Related]
18. Metformin and prostate cancer stem cells: a novel therapeutic target.
Mayer MJ; Klotz LH; Venkateswaran V
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):303-9. PubMed ID: 26215782
[TBL] [Abstract][Full Text] [Related]
19. Targeting Cancer Stem Cells to Overcome Therapy Resistance in Ovarian Cancer.
Muñoz-Galván S; Carnero A
Cells; 2020 Jun; 9(6):. PubMed ID: 32512891
[TBL] [Abstract][Full Text] [Related]
20. Eliminating ovarian cancer stem cells: a potential therapeutic target for ovarian cancer chemoresistance.
Wang X; Li X; Fu X; Bai M; Li X; Mei Q; Nie J; Wu Z; Han W
Curr Protein Pept Sci; 2015; 16(4):270-8. PubMed ID: 25929861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
